<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03666923</url>
  </required_header>
  <id_info>
    <org_study_id>THR-687-001</org_study_id>
    <nct_id>NCT03666923</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)</brief_title>
  <official_title>A Phase 1, Open-label, Multicenter, Dose Escalation Study to Evaluate the Safety of a Single Intravitreal Injection of THR-687 for the Treatment of Diabetic Macular Edema (DME)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ThromboGenics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oxurion</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is conducted to evaluate the safety of a single intravitreal injection of THR-687.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2018</start_date>
  <completion_date type="Actual">November 20, 2019</completion_date>
  <primary_completion_date type="Actual">November 20, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose-limiting toxicities up to the Day 14 visit</measure>
    <time_frame>From Day 0 up to Day 14</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of systemic and ocular adverse events including serious adverse events up to the end of the study</measure>
    <time_frame>From Day 0 up to Day 84</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Occurrence of laboratory abnormalities up to the end of the study</measure>
    <time_frame>At Screening, Day 1, Day 7, Day 28 and Day 84</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Diabetes Mellitus</condition>
  <condition>Diabetic Retinopathy</condition>
  <condition>Diabetic Macular Edema</condition>
  <arm_group>
    <arm_group_label>THR-687 dose level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THR-687 dose level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>THR-687 dose level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive a single intravitreal injection of THR-687 dose level 3</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THR-687 dose level 1</intervention_name>
    <description>single intravitreal injection of THR-687 dose level 1</description>
    <arm_group_label>THR-687 dose level 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THR-687 dose level 2</intervention_name>
    <description>single intravitreal injection of THR-687 dose level 2</description>
    <arm_group_label>THR-687 dose level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>THR-687 dose level 3</intervention_name>
    <description>single intravitreal injection of THR-687 dose level 3</description>
    <arm_group_label>THR-687 dose level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female aged 18 years or older

          -  Type 1 or type 2 Diabetes Mellitus

          -  Central-involved DME with central subfield thickness of ≥ 320µm on Spectralis®
             spectral domain optical coherence tomography (SD-OCT) or ≥ 305µm on non-Spectralis
             SD-OCT, in the study eye

          -  Best-corrected visual acuity (BCVA) ≤ 62 and ≥ 23 ETDRS letter score in the study eye

          -  Written informed consent obtained from the subject prior to screening procedures

        Exclusion Criteria:

          -  Macular edema due to causes other than DME

          -  Concurrent disease in the study eye, other than central-involved DME, that could
             compromise BCVA, require medical or surgical intervention during the study period or
             could confound interpretation of the results

          -  Any condition that could confound the ability to detect a change in central subfield
             thickness in the study eye

          -  Previous confounding treatments / procedures, or expected to require confounding
             treatments / procedures at any time during the study period

          -  Presence of neovascularization at the disc (NVD) in the study eye

          -  Uncontrolled glaucoma in the study eye

          -  Any active ocular / intra-ocular infection or inflammation in either eye

          -  Poorly controlled Diabetes Mellitus

          -  Uncontrolled hypertension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Department</last_name>
    <role>Study Director</role>
    <affiliation>ThromboGenics Inc. A subsidiary of Oxurion NV.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Retina Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85053</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Retina and Macular Disease</name>
      <address>
        <city>Winter Haven</city>
        <state>Florida</state>
        <zip>33880</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Eye Institute</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sierra Eye Associates</name>
      <address>
        <city>Reno</city>
        <state>Nevada</state>
        <zip>89502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Retinal Center</name>
      <address>
        <city>West Columbia</city>
        <state>South Carolina</state>
        <zip>29169</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Retina Research Institute of Texas</name>
      <address>
        <city>Abilene</city>
        <state>Texas</state>
        <zip>79606-1224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Valley Retina Institute, PA</name>
      <address>
        <city>McAllen</city>
        <state>Texas</state>
        <zip>78503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>September 7, 2018</study_first_submitted>
  <study_first_submitted_qc>September 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">September 12, 2018</study_first_posted>
  <last_update_submitted>January 20, 2020</last_update_submitted>
  <last_update_submitted_qc>January 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Diabetic Retinopathy</mesh_term>
    <mesh_term>Edema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

